Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 540 participants.
Also called NCT01313533
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 1/2
- Enrolled
- 540 participants
- Sponsor
- St. Luke's Hospital, Chesterfield, Missouri
- Registry
-
NCT01313533
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT01313533. Randomized; quadruple masking; primary purpose prevention. Start 2015-03 (registry gives no type); primary completion 2019-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes
- Condition
- Atherosclerosis
- Intervention (Drug)
- Polyarginine
- Intervention (Drug)
- Vein soak treated with Lactated Ringers Solution
- Lead sponsor
- St. Luke's Hospital, Chesterfield, Missouri
Record details
- Record id
cardio:ct-nct01313533- Content hash
3aab8feee1fd686494262f01f5045bc832072b4d33164289a21be46211faf121